GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026. The determination relates to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026, and the request has stayed any suspension or delisting action pending the hearing and any extension period that may be granted. Consequently, GeoVax’s common stock is expected to continue trading on The Nasdaq Capital Market under the symbol “GOVX” at least through that period.
The company’s ability to maintain its Nasdaq listing is crucial for several reasons. A continued listing provides access to capital markets, which is essential for a clinical-stage biotechnology company to fund its research and development, clinical trials, and potential commercialization efforts. It also supports investor confidence and facilitates strategic partnerships and funding opportunities. GeoVax intends to present a compliance plan at the hearing to regain and maintain compliance with Nasdaq listing standards. David Dodd, Chairman and CEO, commented, “We remain committed to maintaining GeoVax’s Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution. We continue to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen our manufacturing and global preparedness capabilities, and engage potential strategic, funding and development partners across our portfolio.”
GeoVax’s strategic priorities remain centered on its vaccine and immuno-oncology programs. The lead program, GEO-MVA, is an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. It is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial addressing the need for expanded orthopoxvirus vaccine supply and biodefense preparedness. In parallel, GeoVax is pursuing manufacturing and product innovations to support broader access and preparedness, while evaluating strategic partnerships and funding opportunities. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
Dodd continued, “Our focus remains on building long-term value from GeoVax’s vaccine and immuno-oncology programs while addressing the Company’s near-term corporate and financing priorities. We believe the progress across our programs, together with the growing emphasis on vaccine supply resilience, biodefense preparedness and expanded global access, provides a strong foundation for our continued efforts.”
The Nasdaq listing appeal comes at a critical time for GeoVax. Maintaining its listing is not only about regulatory compliance but also about ensuring the company has the financial flexibility to advance its promising pipeline. The outcomes of the hearing and the company’s ability to regain compliance will be closely watched by investors and partners. For more information about GeoVax, visit www.geovax.com.
